AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998

Reuters08-12

AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998

AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2558649905?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558649905","market":"us","top_or_hot":-1,"title":"AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-12 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLzTl8w:1","article_id":"2558649905","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558649905","pubTimestamp":1754996489,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ANTX":"AN2 Therapeutics, Inc."},"translate_title":"AN2 Therapeutics启动首个潜在治疗恰加斯病的人体临床试验AN2-502998","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9},"content_text":"AN2 Therapeutics Initiates First-in-Human Clinical Trial for Potential Chagas Disease Cure, AN2-502998\n    \n\n        AN2 Therapeutics Inc. has announced the commencement of its first-in-human clinical trial for the drug candidate AN2-502998, intended for the treatment of chronic Chagas disease. This Phase 1 trial aims to evaluate the safety, tolerability, and pharmacokinetics of the oral drug in healthy volunteers. Preclinical studies in nonhuman primates have indicated AN2-502998's potential to cure chronic Chagas disease. With no FDA-approved treatment available for adults with the disease, this development is significant. The company plans to complete Phase 1 dosing by the end of 2025. In collaboration with the Drugs for Neglected Diseases initiative, AN2 Therapeutics is also preparing for a Phase 2 trial, anticipated to start in 2026, with data expected in 2027. Results from the current Phase 1 trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812650698) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2558649905","isCrawlerRequest":true}